Apogee Therapeutics, Inc.(APGE)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
APGE Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Apogee Therapeutics, Inc. (APGE), a Healthcare sector company. APGE is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of APGE by reported 13-F value include FMR, VR Adviser,, WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. APGE trades on the Nasdaq exchange and files with the SEC under CIK 1974640. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate APGE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Apogee Therapeutics, Inc. directly from SEC EDGAR.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-40.5% YoYOperating Income
-31.7% YoYEPS (Diluted)
-27.9% YoYTotal Assets
+24.3% YoYOp. Cash Flow
-32.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Net Income | $-255.8M -40.5% | $-182.1M -116.9% | $-84.0M -111.1% | $-39.8M |
| Operating Income | $-285.6M -31.7% | $-216.9M -133.2% | $-93.0M -202.7% | $-30.7M |
| EPS (Diluted) | $-4.22 -27.9% | $-3.30 +1.8% | $-3.36 +79.2% | $-16.16 |
| Total Assets | $937.1M +24.3% | $754.0M +87.8% | $401.4M +164.0% | $152.1M |
| Operating Cash Flow | $-227.4M -32.9% | $-171.2M -129.0% | $-74.8M -355.1% | $-16.4M |
AI Insight: APGE Ratio Trends
Apogee remains unprofitable but ROA loss rate narrowed sharply from -41.5% in Q3 2025 to -22.9% in Q1 2026.
• ROA deteriorated from -16.9% in Q2 2024 to -41.5% in Q3 2025, then recovered to -22.9% in Q1 2026—suggesting cost control or improved operational leverage.
• TTM ROA of -21.2% reflects cumulative Q2 2025–Q1 2026 period; company remains cash-flow negative overall.
⚠ Sustainability of Q1 2026 improvement uncertain; only one quarter of visible recovery after multi-quarter deterioration.
⚠ No OpMargin, NPM, ROE, or leverage data available—limits visibility into profitability path and balance-sheet health.
Get alerted when APGE's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Apogee Therapeutics, Inc. including:
Top Institutional Holders of APGE
FMR LLC
$779.6M9,262,291 shVR Adviser, LLC
$714.9M8,493,321 shWELLINGTON MANAGEMENT GROUP LLP
$368.3M4,375,703 shBlackRock, Inc.
$343.9M4,085,651 shRTW INVESTMENTS, LP
$234.2M2,782,097 shVANGUARD CAPITAL MANAGEMENT LLC
$210.6M2,502,095 shJANUS HENDERSON GROUP PLC
$198.8M2,360,596 shSTATE STREET CORP
$182.1M2,162,964 shDRIEHAUS CAPITAL MANAGEMENT LLC
$161.7M1,920,800 shPERCEPTIVE ADVISORS LLC
$129.7M1,540,384 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $779.6M | 9,262,291 |
| VR Adviser, LLC | $714.9M | 8,493,321 |
| WELLINGTON MANAGEMENT GROUP LLP | $368.3M | 4,375,703 |
| BlackRock, Inc. | $343.9M | 4,085,651 |
| RTW INVESTMENTS, LP | $234.2M | 2,782,097 |
| VANGUARD CAPITAL MANAGEMENT LLC | $210.6M | 2,502,095 |
| JANUS HENDERSON GROUP PLC | $198.8M | 2,360,596 |
| STATE STREET CORP | $182.1M | 2,162,964 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $161.7M | 1,920,800 |
| PERCEPTIVE ADVISORS LLC | $129.7M | 1,540,384 |
More Healthcare Companies
View all Healthcare →Put APGE on your watchlist
Track score changes the day Apogee Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is APGE a good stock to buy?
13F Pro's AI-powered analysis of Apogee Therapeutics, Inc. (APGE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for APGE are available on the APGE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own APGE?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling APGE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Apogee Therapeutics, Inc.'s investment landscape.